Pfizer lays out two phases of COVID-19 vaccine pricing

Developed countries won’t be charged less than the U.S. for Pfizer and BioNTech’s COVID-19 vaccine, though the U.S. company anticipates recalibrating the price based on value after the pandemic subsides.

The pricing comments came Tuesday on a conference call to discuss Pfizer’s earnings, and follow a $2 billion deal to provide the U.S. government with 100 million doses of BNT162b2 (see “U.S. Shows It’s Willing to Pay More Per Dose”)...